Replies to post #453433 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The point of course is explaining that plasma abeta 42/40 ratio isn't an accepted biomarker of amyloid load, PET scan is!

In the Lecanemab trial a key secondary endpoint was indeed the change in amyloid burden on PET, not plasma abeta 42/40. So Anavex comparing something not accepted to something not accepted may be indicative, but not conclusive. Especially since establishing PET amyloid burden at baseline was not a mandatory inclusion criteria in the P2b/3 trial and there is no baseline nor is any endpoint measure of PET amyloid burden. There was in the Lecanemab trial!

Hope you get it now or was it just an honest deflection?

Anavex is pretending to legitimise abeta 42/40 ratio as a biomarker and making a meal of something that will be a regulatory side note.